ViperX Laboratory

This trial is a randomized, double-blinded, placebo-controlled trial, addressing the hypothesis that short duration of high-dose n-3 PUFA oral supplementation improves endothelial function (EF) and inflammation in subjects with PAD. In this study, eighty patients with stable, mild-severe claudication and ABI< 0.9 received fish oil (Fish) or placebo capsules (Placebo) for 1 month.

This trial is a double-blinded, randomized, placebo-controlled trial that examines the hypothesis that high-dose n-3 PUFA oral supplementation improves systemic inflammation, vascular function, and symptomatic status of patients with PAD. To accomplish this, about twenty patients aged ≥ 50 with mild-severe claudication received n-3 PUFA orally for 3 months versus a placebo. The results helped identify inflammatory biomarkers in congruence with fatty acids in the blood.

This trial is a double-blind, randomized, placebo-controlled trial with 30 patients aged ≥ 40 years, undergoing some sort of peripheral vascular intervention for PAD. The patients receive n-3 PUFA supplementation or placebo, pre- and post-operatively. Omega PVI provided important new insights on the role of nutritional interventions in PAD, as well as to improve outcomes related to surgical revascularization

This is a single center, Phase II, double-blind, placebo-controlled, randomized trial. Approximately 30 subjects will be randomized to fish oil or placebo, for up to six months. With 2

The overall goal of the study is to determine the relationship between systemic inflammation as measured by a panel of circulating biomarkers, endothelial function of the vein graft, and early luminal remodeling of the vein graft. In a cohort of patients undergoing lower extremity bypass, plasma markers of inflammation and endothelial activation (C-reactive protein (CRP), monocyte chemotactic protein 1 (MCP-1), serum thrombomodulin, and soluble E-selectin and P-selectin), will be related to systemic endothelial function (brachial artery) as well as vein graft-specific endothelial function. Human in vivo endothelial function of lower extremity vein grafts has never been previously measured. For this study, endothelial function was assessed in the vein graft as well as the brachial artery. A cuff occlusion technique similar to that which is commonly used in the arm to asses flow-mediated, endothelium-dependent vasoreactivity of the vein graft at 3, 6 and 12 months post-implantation. Vein graft remodeling was assessed by measuring early lumen changes of the vein graft from the time of implantation until 12 months.

In collaboration with the University of Washington Vascular Team, this is a multicenter prospective, randomized trial, with SFVAMC acting as the coordinating center. This study is looking to determine the mechanism of healing following a superficial femoral or popliteal angioplasty. This study aims to investigate if patient specific parameters affect angioplasty outcomes, if dexamethasone has a biological effect on the vessel wall and its effects in its reduction to inflammation.

An arterio-venous fistula is a surgical procedure that supports access for people undergoing hemodialysis (HD) for End Stage Renal Disease (ESRD). This observational pilot study seeks to better understand the factors that contribute to the successful maturation of an arterio-venous fistula. A primary aim of this study is to see if endothelial function (the biochemical events initiated by cells lining the arteries) is associated with successful maturation. Other aims include determining if pro-inflammatory markers in the blood or evidence of gene expression are associated with successful maturation.